NeoGenomics (NEO), a leading oncology testing services company, experienced a significant plummet of 12.34% in pre-market trading on Tuesday, February 18, 2025, after reporting its fourth-quarter and full-year 2024 results.
The company's fourth-quarter revenue of $172 million fell short of Wall Street's expectations of $173.2 million, despite a year-over-year increase of 11%. NeoGenomics also missed analyst estimates for its fourth-quarter earnings, reporting an adjusted earnings per share (EPS) of $0.04, slightly above the consensus estimate of $0.03.
However, the more significant factor contributing to the stock's plummet was the company's full-year 2025 guidance, which failed to meet investor expectations. While NeoGenomics reaffirmed its revenue guidance range of $735 million to $745 million for 2025, representing growth of 11% to 13% year-over-year, the midpoint of $740 million was only 0.7% above analysts' estimates. Furthermore, the company's adjusted EPS guidance range of $0.15 to $0.19 for 2025 disappointed investors, with the midpoint of $0.17 falling short of the consensus estimate of $0.20.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。